Posted by Michael Wonder on 10 Oct 2018
Institute for Clinical and Economic Review to publish upcoming assessments on treatments for secondary progressive multiple sclerosis, treatment-resistant depression
10 October 2018 - Both reports will be subject of Midwest CEPAC meeting in May 2019.
The ICER will assess the comparative clinical effectiveness and value of new therapies for secondary progressive multiple sclerosis (SPMS) and treatment-resistant depression in upcoming reports. Both reports are set to be reviewed during a public meeting of the Midwest Comparative Effectiveness Public Advisory Council (Midwest CEPAC) in May of 2019.
The SPMS review is expected to assess the clinical effectiveness and value of siponimod (Novartis), which is currently undergoing FDA review with an approval decision expected in March 2019.
The treatment-resistant depression review is expected to assess the clinical effectiveness and value of esketamine (Janssen), which is currently undergoing FDA review with an approval decision expected in May 2019.
